HomeGeneticsConditionX-linked thrombocytopenia
Back to Condition
X-linked thrombocytopenia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

X-linked thrombocytopenia

X-linked thrombocytopenia is a bleeding disorder primarily affecting males, characterized by a shortage of abnormally small platelets, leading to easy bruising and prolonged bleeding.

Overview

X-linked thrombocytopenia is a bleeding disorder that primarily affects males. This condition is characterized by a blood cell abnormality called thrombocytopenia, which is a shortage in the number of blood cells involved in clotting (platelets). Affected individuals often have abnormally small platelets as well, a condition called microthrombocytopenia. X-linked thrombocytopenia can cause individuals to bruise easily or have episodes of prolonged bleeding following minor trauma or even in the absence of injury (spontaneous bleeding). Some people with this condition experience spontaneous bleeding in the brain (cerebral hemorrhage), which can cause brain damage that can be life-threatening.

Some people with X-linked thrombocytopenia also have patches of red, irritated skin (eczema) or an increased susceptibility to infections. In severe cases, additional features can develop, such as cancer or autoimmune disorders, which occur when the immune system malfunctions and attacks the body's own tissues and organs. It is unclear, however, if people with these features have X-linked thrombocytopenia or a more severe disorder with similar signs and symptoms called Wiskott-Aldrich syndrome.

Some people have a mild form of the disorder called intermittent thrombocytopenia. These individuals have normal platelet production at times with episodes of thrombocytopenia.

Frequency

The estimated incidence of X-linked thrombocytopenia is between 1 and 10 per million males worldwide; this condition is rarer among females.

Causes & Risk Factors

Mutations in the WAS gene cause X-linked thrombocytopenia. The WAS gene provides instructions for making a protein called WASP. This protein is found in all blood cells. WASP is involved in relaying signals from the surface of blood cells to the cytoskeleton, which is a network of fibers that make up the cell's structural framework. WASP signaling activates the cell when it is needed and triggers its movement and attachment to other cells and tissues (adhesion). In white blood cells, which protect the body from infection, this signaling allows the actin cytoskeleton to establish the interaction between cells and the foreign invaders that they target (immune synapse).

WAS gene mutations that cause X-linked thrombocytopenia typically lead to the production of an altered protein. The altered WASP has reduced function and cannot efficiently relay signals from the cytoskeleton to the actin cytoskeleton. In people with X-linked thrombocytopenia, these signaling problems primarily affect platelets, impairing their development. In some cases, white blood cells are affected. When WASP function is impaired in white blood cells, they are less able to respond to foreign invaders and immune problems such as infections, eczema, and autoimmune disorders can occur.

Associated Gene

  • WAS

Inheritance

This condition is inherited in an X-linked pattern. The gene associated with this condition is located on the X chromosome, which is one of the two sex chromosomes. In females (who have two X chromosomes), a mutation in one of the two copies of the gene in each cell may or may not cause the disorder. In males (who have only one X chromosome), a mutation in the only copy of the gene in each cell causes the disorder. In most cases of X-linked inheritance, males experience more severe symptoms of the disorder than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Other Names

  • Thrombocytopenia 1
  • XLT

Frequently Asked Questions

spirin and non‑steroidal anti‑inflammatory drugs (NSAIDs) inhibit platelet aggregation and can worsen bleeding in X‑linked thrombocytopenia. It is safest to avoid these medications unless a doctor prescribes a low‑dose alternative and monitors your platelet count. Use acetaminophen for pain instead.
Supportive care includes platelet transfusions for major bleeding and antifibrinolytic agents (e.g., tranexamic acid) for mucosal bleeding. Thrombopoietin receptor agonists (eltrombopag, romiplostim) have shown promise in increasing platelet counts in some patients, but their use must be weighed against potential side effects. Experimental gene‑therapy trials are underway, but are not yet widely available. Always consult a hematologist before starting any new therapy.===
The risk of a silent brain bleed is higher in men with very low platelet counts (<50,000) or a history of severe bleeding. Regular neurological exams, MRI or CT scans if symptoms arise (headache, weakness, vision changes), and maintaining a low‑impact lifestyle can help detect problems early. Discuss a personalized surveillance plan with your provider.
normal platelet count ranges from 150,000 to 450,000 per microliter. In X‑linked thrombocytopenia, counts often fall below 100,000, and platelet size (mean platelet volume) is usually reduced. If your count is under 80,000 or you notice unusually small platelets on a peripheral smear, you should discuss bleeding precautions with your hematologist.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA